178 related articles for article (PubMed ID: 23319072)
1. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Tur C; Tintoré M; Horga A; Auger C; Río J; Nos C; Edo MC; Arévalo MJ; Castilló J; Rovira A; Montalban X
Mult Scler; 2013 Aug; 19(9):1175-81. PubMed ID: 23319072
[TBL] [Abstract][Full Text] [Related]
2. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
Magraner M; Coret F; Casanova B
Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
[TBL] [Abstract][Full Text] [Related]
3. Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.
Dolezal O; Gabelic T; Horakova D; Bergsland N; Dwyer MG; Seidl Z; Krasensky J; Ramasamy DP; Vaneckova M; Havrdova E; Zivadinov R
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S42-8. PubMed ID: 24321154
[TBL] [Abstract][Full Text] [Related]
4. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
[TBL] [Abstract][Full Text] [Related]
5. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
7. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of early brain atrophy in clinically isolated syndromes.
Pérez-Miralles F; Sastre-Garriga J; Tintoré M; Arrambide G; Nos C; Perkal H; Río J; Edo MC; Horga A; Castilló J; Auger C; Huerga E; Rovira A; Montalban X
Mult Scler; 2013 Dec; 19(14):1878-86. PubMed ID: 23652215
[TBL] [Abstract][Full Text] [Related]
9. Brain volume increase after discontinuing natalizumab therapy: Evidence for reversible pseudoatrophy.
Nakamura K; Elliott C; Lee H; Narayanan S; Arnold DL
Mult Scler Relat Disord; 2024 Jan; 81():105123. PubMed ID: 37976981
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
[TBL] [Abstract][Full Text] [Related]
11. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis.
Young KL; Brandt AU; Petzold A; Reitz LY; Lintze F; Paul F; Martin R; Schippling S
Eur J Neurol; 2013 May; 20(5):803-11. PubMed ID: 23369013
[TBL] [Abstract][Full Text] [Related]
12. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
[TBL] [Abstract][Full Text] [Related]
14. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
15. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Khan O; Bao F; Shah M; Caon C; Tselis A; Bailey R; Silverman B; Zak I
J Neurol Sci; 2012 Jan; 312(1-2):7-12. PubMed ID: 21920559
[TBL] [Abstract][Full Text] [Related]
16. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
[TBL] [Abstract][Full Text] [Related]
17. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
[TBL] [Abstract][Full Text] [Related]
18. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.
Tiberio M; Chard DT; Altmann DR; Davies G; Griffin CM; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
Neurology; 2005 Mar; 64(6):1001-7. PubMed ID: 15781816
[TBL] [Abstract][Full Text] [Related]
19. Brain atrophy in clinically early relapsing-remitting multiple sclerosis.
Chard DT; Griffin CM; Parker GJ; Kapoor R; Thompson AJ; Miller DH
Brain; 2002 Feb; 125(Pt 2):327-37. PubMed ID: 11844733
[TBL] [Abstract][Full Text] [Related]
20. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
